Atherosclerotic heart disease of native coronary artery without angina pectoris is plaque buildup in your own coronary arteries that has not produced chest pain. The words "without angina pectoris" are the boundary: the disease is present, but the classic symptom is absent. What fills that gap is important, because roughly 20% to 40% of people with confirmed coronary artery disease report no chest pain at all, according to a 2018 American Heart Association scientific statement on silent myocardial ischemia. The diagnosis rests on objective testing, not on how you feel.
Why "Without Angina Pectoris" Is a Separate Diagnostic Label
ICD-10-CM, the coding system U.S. clinicians use for billing and records, splits this condition across two codes. I25.10 is "atherosclerotic heart disease of native coronary artery without angina pectoris." I25.11 is the same disease with angina. That one-digit difference carries real consequences for how your chart reads.
The word "native" distinguishes your original arteries from bypass grafts or stents, which get their own codes (I25.810 for a failed graft, for example). If your disease sits in a vessel you were born with, not a surgically added conduit, the native label applies.
The label describes a clinical state at a moment in time. A person coded I25.10 today can become I25.11 if angina appears later, and the reverse happens after successful revascularization. The code tracks the symptom relationship, not the plaque burden itself.
Without angina, the diagnosis has to be earned through imaging or stress testing. A cardiologist cannot code I25.10 from symptoms alone, because "no pain" is not a symptom. That's the structural difference between this label and a routine chest-pain workup.
What the Plaque Is Doing When There Is No Pain
Atherosclerosis begins with endothelial injury, followed by lipid deposition, macrophage infiltration, and smooth-muscle proliferation. The result is a fibrous cap over a lipid-rich core. According to the landmark 1995 Circulation paper by Davies on plaque stability, the plaques most likely to rupture are not necessarily the ones causing the tightest narrowing.
Silent disease can be either stable and non-obstructive or unstable and vulnerable. A 30% stenosis with a thin fibrous cap can rupture and cause an acute event, while an 80% stenosis with a thick cap may produce no symptoms at rest. That's why "no angina" is not reassurance about risk.
Coronary flow reserve explains part of the silence. Symptoms typically appear when demand outstrips supply, and a sedentary person may never cross that threshold. A person who walks two blocks and sits the rest of the day may genuinely never provoke ischemia severe enough to register as pain.
Diabetic autonomic neuropathy is a documented cause of silent infarction. A 2014 review in the Journal of Nuclear Cardiology on silent ischemia notes that people with long-standing diabetes often have blunted anginal warning. The same neuropathy that numbs the feet can mask cardiac pain signals.
How This Diagnosis Is Actually Confirmed
Testing follows a logical ladder, and each rung has a specific role. The choice depends on whether you can exercise, what your resting ECG shows, and what the clinician is trying to rule out.
| Test | Best Use | Key Limitation | Typical Sensitivity |
|---|---|---|---|
| Exercise treadmill ECG | First-line for exercise-capable patients | Uninterpretable with LBBB or paced rhythm | 68% (per 2010 ACC/AHA appropriateness criteria) |
| Stress echocardiography | Adds wall-motion data | Reader-dependent | 80–85% |
| Coronary CT angiography (CCTA) | An anatomical view of plaque | Overestimates stenosis severity | 95%+ for stenosis ≥50% |
| Invasive coronary angiography | Gold standard; allows intervention | Catheter-based risk; contrast load | Reference standard |
| Cardiac MRI perfusion | Tissue-level ischemia | Limited availability, longer scan time | 85–90% |
A 2020 meta-analysis in the Journal of the American College of Cardiology on CCTA found that patients with non-obstructive plaque (under 50% stenosis) still had a 1.5% annual major adverse cardiac event rate. That number is the crucial one: "without angina" does not mean "without risk."
If you can walk briskly on a treadmill, exercise ECG is often the cheapest gatekeeper, typically several hundred dollars in the U.S. versus $1,000–$3,000 for CCTA depending on region and insurance. Your clinician picks based on your ability to exercise and your baseline ECG, not on cost alone.
The Symptom Substitutes That Get Missed
Absent chest pain does not mean absent symptoms. Silent ischemia frequently announces itself through equivalents, and these are the ones people dismiss. A 2003 study of 3,000+ patients in the Journal of the American Medical Association on women with coronary disease found shortness of breath, fatigue, and sleep disturbance were among the earliest presenting complaints.
The common equivalents: exertional breathlessness disproportionate to your fitness, unexplained jaw or throat tightness, nausea with exertion, and a sudden drop in exercise tolerance. Any of these with a cardiac risk profile deserves the same workup as classic chest pain.
The failure case is the person who normalizes the equivalent. "I just get winded" becomes the story for six months, until an event brings them in. Clinicians call this diagnostic creep, and it's why family history and risk factors matter as much as the symptom inventory.
If your resting ECG is normal and you have no symptoms, you may never be tested at all. That's a legitimate gap in screening, not a flaw in your body. The U.S. Preventive Services Task Force does not recommend routine screening in asymptomatic adults, so this label often arrives from an incidental finding on a scan ordered for something else.
Who Ends Up With This Code on Their Chart
Three clinical pathways lead here. First, incidental coronary calcification on a chest CT ordered for lung screening or pre-surgical clearance. Second, a stress test performed for another reason that shows inducible ischemia but no reported pain. Third, a cardiac catheterization that reveals disease anatomy without matching symptoms.
The cardiac rehab population is one group. People who underwent an event or procedure get enrolled, and their follow-up coding often reflects native disease without angina once the event resolves. Exercise capacity in rehab is a strong prognostic marker here.
The preoperative clearance group is another. A surgeon orders a stress test before non-cardiac surgery, and a borderline abnormal result with no chest pain generates this label. That label can delay or reshape surgical planning, even if the person has lived with it for years without incident.
The incidental-scan group is the fastest-growing with the spread of low-dose CT for lung cancer screening. A coronary artery calcification score above 100 on a screening scan, with no symptoms, is enough to enter this diagnostic category. The 2019 ACC/AHA primary prevention guideline treats a CAC score of 100+ as a modifier that supports statin initiation in intermediate-risk adults.
Risk in the Silent Form, Quantified
The absence of angina changes symptom management, not mortality risk. A 2017 JAMA Cardiology analysis of coronary CT registry data found that the 5-year event rate for non-obstructive disease (1–49% stenosis) was 3.9%, while for obstructive disease (≥50%) it was 14.6%. Symptom status did not reclassify those risks by much.
Statin therapy is the backbone of management here. The 2018 ACC/AHA cholesterol guideline recommends moderate-to-high-intensity statins for anyone with clinical atherosclerotic cardiovascular disease, and the presence of this diagnosis is clinical ASCVD. A 2018 meta-analysis of 27 randomized trials in the Lancet (Cholesterol Treatment Trialists' Collaboration) found roughly a 22% relative risk reduction in major vascular events per 1 mmol/L (39 mg/dL) LDL drop.
LDL target for most patients with this label is below 70 mg/dL, and below 55 mg/dL if you're very high risk by the 2018 guideline's criteria. Verifying what applies to you requires your cardiologist, not a general table.
The cost question is real. Generic atorvastatin typically runs $4–$15 per month through U.S. discount programs, while branded options can run $300 or more. Cost is a legitimate reason to ask for a generic switch, and it's rarely clinically worse for equivalent dosing.
Does the Label Change the Treatment Plan?
Not much, and that surprises people. The treatment algorithm for ASCVD depends on plaque burden, risk factors, and event history, not on whether the symptoms surfaced as chest pain. Statins, antiplatelet therapy in select cases, blood pressure control, and lifestyle changes apply regardless.
Antiplatelet decisions differ. Aspirin for primary prevention in this population is debated; the 2022 USPSTF recommendation narrowed aspirin use to adults 40–59 at higher risk, and advised against starting it at 60+. Your clinician's decision here should be individualized, and it will not be made from the code label alone.
Revascularization is the big exception. If you have no angina but you have a critical lesion (left main disease, or a proximal LAD lesion above 70%), PCI or CABG may still be indicated on prognostic grounds. A 2019 Lancet meta-analysis of revascularization trials found that prognostic benefit was concentrated in specific anatomical subsets, largely independent of symptoms.
If your disease is non-obstructive and you have no symptoms, expect the plan to be medical therapy and surveillance imaging, not a catheter lab referral. That's the pragmatic split between this label and its symptomatic counterpart.
Coding and Documentation Pitfalls
Medical coders distinguish "native" from "graft" and "without angina" from "with angina" using specific documentation. A 2023 audit note from the American Health Information Management Association on cardiovascular coding flags that I25.10 requires the provider to document both the atherosclerosis and the absence of angina. If a note says "CAD, no symptoms," a coder may default to I25.10, but an ambiguous note risks an I25.11 code and a downstream query.
Insurance can treat this as a chronic condition for prior authorization purposes. A moderate calcium score documented under I25.10 can support statin authorization or diagnostic follow-up, but a bare code without supporting documentation can be denied.
Patients who change providers sometimes find the label follows them without context. The chart entry says I25.10, but no one remembers what produced it. If you see this diagnosis and don't recognize it, ask which test generated it. The answer tells you whether it was an incidental finding or a substantive workup.
Five-Year Monitoring Schedule for a Silent Diagnosis
Surveillance is not annual for everyone. Frequency depends on stenosis severity, calcium score, and risk factors. The following schedule reflects what most preventive cardiology practices use, and your clinician may modify it.
1: Year 1: Repeat lipid panel at 3 months and 12 months after starting a statin, to confirm LDL drop of at least 50% or achievement of the target below 70 mg/dL. Blood pressure review at every visit. 2: Years 2–3: Lipid panel every 6–12 months if stable. Resting ECG annually if you have hypertension or diabetes. Repeat stress imaging only if symptoms change. 3: Year 3 or later: Repeat coronary CT angiography or calcium scoring if the initial finding was non-obstructive and risk factors remain uncontrolled. 4: Ongoing: Escalate testing immediately if an anginal equivalent appears, regardless of the schedule. New exertional breathlessness is the trigger that overrides any calendar.
The failure path is skipping the schedule because you feel fine. The 2019 primary prevention guideline names non-adherence to statins as one of the largest modifiable contributors to residual risk. If cost, side effects, or muscle complaints interrupt the regimen, tell your clinician rather than stopping quietly.
What People Get Wrong About the Word "Without"
The biggest misconception is that "without angina" means mild disease. It does not. A 2020 CCTA study in Circulation: Cardiovascular Imaging on 5,000 patients found that 45% of people with non-obstructive disease carried high-risk plaque features such as positive remodeling or low attenuation. Those features are silent and consequential.
The second misconception is that the code clears you from further investigation. It documents a state, not a prognosis. If you develop symptoms later, the code changes; if you have a critical lesion without symptoms, your clinician can still act on anatomy alone.
The misuse: some patients treat "no angina" as evidence that exercise is dangerous. The opposite is usually true. Supervised exercise, including cardiac rehabilitation where eligible, is recommended for stable coronary disease under the 2020 ACC/AHA guideline on sports and exercise. Unsupervised strenuous exertion without clearance is the actual risk, not movement itself.
The condition is common enough that you will encounter it in other people's charts, and seeing it in your own isn't automatically alarming. It's a snapshot. Understanding what produced it, and what you're doing about it now, matters more than the label's wording.
FAQ
Can I have this diagnosis and never have a heart attack?
Absolutely, and many people don't. The 2017 JAMA Cardiology registry data on non-obstructive disease shows a 3.9% five-year event rate, meaning the large majority of people with this label avoid an event over five years when risk factors are managed. Risk is not zero, but it is substantially lower than commonly feared. The label's purpose is to prompt management, not to predict doom.
Is I25.10 the same as I25.11?
They share the atherosclerosis but split on symptom relationship. I25.11 adds angina pectoris, and that symptom difference can shift treatment toward antianginal medication and revascularization discussion. If a patient reports chest pain in a visit, a coder may move the code from I25.10 to I25.11. Verify the current code set on the CMS ICD-10-CM page, since codes get revised in October of each year.
What if I develop chest pain next month?
Call your clinician or emergency services depending on severity. A new symptom changes the code from I25.10 to I25.11 and warrants re-evaluation, possibly with a stress test or catheterization. Sudden, severe chest pain with sweating, nausea, or radiating arm pain is a 911 call, not a wait-and-see. Don't self-assess severity from a prior silent diagnosis.
Does "native coronary artery" exclude stents?
Yes. Native refers to your original vessels. Once a stent or bypass graft is placed, coding can shift to graft or stent status categories. The native label is a baseline marker, and it is often used alongside stent status codes rather than replaced by them. If you've had stents, ask which code leads on your chart.
How much does the statin typically cost?
Generic atorvastatin runs roughly $4–$15 per month through U.S. discount pharmacy programs and often less with insurance, according to commonly published cash-price trackers. Branded statins can exceed $300 per month without coverage. If cost blocks adherence, ask for a generic switch, prior authorization, or patient assistance.
Can I skip the statin if I feel fine?
No. The 2018 ACC/AHA cholesterol guideline treats this diagnosis as clinical ASCVD, and statins reduce events independent of symptoms. The 2018 Cholesterol Treatment Trialists' meta-analysis found a 22% relative risk reduction per 39 mg/dL LDL drop. Feeling fine is not a substitute for treatment, and stopping without discussing it with your clinician leaves risk unmanaged.
Is exercise safe with silent ischemia?
For most people with stable, non-obstructive disease, yes, and regular moderate exercise is recommended by the 2020 ACC/AHA sports and exercise guideline. The edge case is a high-risk anatomical lesion or uncontrolled symptoms, where exercise needs cardiology clearance first. Ask for clearance before starting vigorous activity, especially if you're sedentary now.
Can an incidental calcium score cause this diagnosis?
Yes, and this is one of the most common paths. A CAC score of 100 or higher on a lung or chest CT supports clinical ASCVD classification under the 2019 ACC/AHA primary prevention guideline. That score doesn't make the diagnosis by itself; a clinician correlates it with risk factors. The finding is often the first sign someone gets, because there are no symptoms to prompt testing.
This article is general educational information, not a diagnosis, treatment plan, or medical advice. Atherosclerotic disease decisions depend on your individual anatomy, risk factors, and test results, so discuss any code or label on your chart with a qualified local cardiologist or primary care clinician before acting on it. If you have sudden chest pain, severe shortness of breath, or any emergency symptom, call local emergency services such as 911 in the United States immediately.